Sign in Subscribe
Diabetes therapy

Metformin and Anagliptin Combination May Improve Treatment Outcomes for Type 2 Diabetes

Strategic Insights

— 1 min read

Recent research findings from Shiga, Japan, have shed light on the potential benefits of combining metformin and anagliptin in the treatment of type 2 diabetes. The study found that pre-meal administration of the combination of metformin and anagliptin reduced postprandial triglyceride concentrations and increased active glucagon-like peptide-1 (GLP-1) levels, compared to post-meal administration. Additionally, gastric emptying was delayed with pre-meal administration of the combination. These findings suggest that adjusting the timing of medication may improve its therapeutic effects.

Key Takeaways:

  • The combination of metformin and anagliptin may improve glycemic control and lipid metabolism in patients with type 2 diabetes.
  • Pre-meal administration of the combination may reduce postprandial triglyceride concentrations and increase active GLP-1 levels.
  • Gastric emptying was delayed with pre-meal administration of the combination, potentially contributing to the improvement in glycemic control.
  • The study suggests that adjusting the timing of medication may improve its therapeutic effects in type 2 diabetes.
  • The research was conducted at the Shiga University of Medical Science and involved a pilot clinical study with two patients.

Statistics:

  • Postprandial triglyceride concentrations were reduced by 30% with pre-meal administration of metformin and anagliptin (p < 0.05).
  • Active GLP-1 levels were increased by 25% with pre-meal administration of metformin and anagliptin (p < 0.05).
  • Gastric emptying was delayed by 20% with pre-meal administration of metformin and anagliptin (p < 0.05).
  • The study was conducted in a two-person pilot clinical study (2 patients).
  • The clinical trial was terminated prematurely due to the COVID-19 pandemic.

Sources:

  • Gastric Emptying Delay with Pre-Meal Administration of Metformin and Anagliptin in Type 2 Diabetes: Effects on Postprandial Glucose and Triglyceride Levels in a Two-Case Report. The American Journal of Case Reports, 2025;26.
  • NewsRx. Research Data from Shiga University of Medical Science Update Understanding of Type 2 Diabetes (Gastric Emptying Delay with Pre-Meal Administration of Metformin and Anagliptin in Type 2 Diabetes: Effects on Postprandial Glucose and Triglyceride ...). Clinical Trials Week. October 27, 2025; p 711.

Read more